 NEW YORK, June 7, 2021 PRNewswire -- Synaptogenix, Inc. Nasdaq: SNPX, an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today issued a statement following the announced FDA approval of Biogens new Alzheimers treatment Aducanumab. Daniel Alkon, M.D. 